Clinical Trial · NCT01916135

PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative

Overview

This study is the first time that a new experimental drug called \[18F\]-SKI-249380 is being used in people. \[18F\]-SKI-249380 is not a therapeutic drug. \[18F\]-SKI-249380 is a drug that will be used with PET scanners to 'see' where \[18F\]-SKI-249380 goes in the body, after its injected. The researchers believe that scans with \[18F\]-SKI-249380 might be able to find tumors in patients. This study is being done to see how long \[18F\]-SKI-249380 stays in the blood, when it is given to people in tiny amounts by an injection into a vein in their arm, and to see where \[18F\]-SKI-249380 goes in the body. If the results of this trial are good, then the study doctors plan to use \[18F\]-SKI-249380 in another trial to see if scans with \[18F\]-SKI-249380 are better for finding tumors compared to the standard types of scans that doctors use.

Sponsor

Memorial Sloan Kettering Cancer Center

Phase

Phase 1

Contacts

Mark Dunphy, D.O. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01916135

Eligibility

Inclusion

Patients with history of histologically-confirmed neoplasm of any of the following classifications: solid malignancy, myeloid neoplasm, lymphoid neoplasm.
Radiologically-measurable or evaluable as defined by tumor response criteria from an MSKCC-IRB approved clinic research protocol.
Disease that is either:
Detectable by biopsy (eg, bone marrow) and/or peripheral blood assays obtained within 6 weeks of study enrollment
Not breast-feeding, if applicable.
Histology confirmed by MSKCC Department of Pathology.

Exclusion

AST/ALT \>2.5 x ULN
Acute major illness (e.g., unstable cardiovascular condition, etc.)
Refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia)
GGT \> 2.5 x ULN IF Alkaline phosphatase \> 2.5 x ULN.
Renal: Creatinine \>1.5 x ULN or creatinine clearance \< 60 mL/min, from assays obtained \<2 weeks prior to study enrollment
Bilirubin \> 1.5 x institutional upper limit of normal (ULN)
Albumin \< 2 g/dl
Inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of \[18F\]-SKI-249380 injection and blood draws.)
Hepatic: from assays obtained \<2 weeks prior to study enrollment
Refusal or inability to discontinue medications or other substances (eg, foods or dietary supplements) that may affect \[18F\]-SKI-249380 metabolism. Notably, as dasatinib metabolism is CYP3A4-dependent, the metabolism of \[18F\]-SKI-249380 may be altered by inhibitors and inducers of cytochrome P450 isoenzyme CYP3A4. The acceptability of medications and other substances used by the patient will be determined by the study investigators.